12 Delahunt B, Eble JN, Mccredie MR, et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases[J]. Hum Pathol, 2001, 32(6): 590-595.
[3]
13 Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma[J]. Rev Urol, 2002, 4(4): 163-170.
15 Rosenberg SA. Gene therapy for cancer[J]. JAMA, 1992, 268(17): 2416-2419.
[6]
16 Shiba M, Nonomura N, Nakai Y, et al. Type-Ⅰinterferon receptor expression: its circadian rhythm and downregulation after interferon-alpha administration in peripheral blood cells from renal cancer patients[J]. Int J Urol, 2009, 16(4): 356-359.
[7]
17 Gery I, Gershon RK, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell[J]. J Exp Med, 1972, 136(1): 128-142.
[8]
1 Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method[J]. Cancer, 2012, 118(18): 4427-4436.
[9]
2 Nepple KG, Yang L, Grubb RL, et al. Population based analysis of the increasing incidence of kidney cancer in the United States: evaluation of age specific trends from 1975 to 2006[J]. J Urol, 2012, 187(1): 32-38.
[10]
3 Cohen HT, Mcgovern FJ. Renal-cell carcinoma[J]. N Eng J Med, 2005, 13(2): 2477-2490.
5 Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors[J]. Semin Immunol, 2007, 19(1): 3-10.
[13]
6 Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors[J]. Curr Opin Immunol, 2003, 15 (4): 396-401.
[14]
7 Sch?n MP, Sch?n M. TLR7 and TLR8 as targets in cancer therapy[J]. Oncogene, 2008, 27(2): 190-199.
[15]
8 Ghosh TK, Mickelson DJ, Solberg JC, et al. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha[J]. Int Immunopharmacol, 2007, 7(8): 1111-1121.
18 Montagna D, Turin I, Schiavo R, et al. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor[J]. Cytotherapy, 2012, 14(1): 80-90.
[19]
19 Dillman RO. Cancer immunotherapy[J]. Cancer Biother Radiopharm, 2011, 26(1): 1-64.
[20]
20 Galanis E, Burch PA, Richardson RL, et al. Intratumoral administration of a 1, 2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/ dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma[J]. Cancer, 2004, 101(11): 2557-2566.
22 Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nat Immunol, 2010, 11(5): 373-384.
[23]
23 Kaisho T, Akira S. Toll-like receptor function and signaling[J]. J Allergy Clin Immunol, 2006, 117(5): 979-987; quiz 988.
[24]
24 Smits EL, Cools N, Lion E, et al. The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells[J]. Cancer Immunol Immunother, 2010, 59(1): 35-46.